Centro Hospitalar de Lisboa Central — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications6liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
DexmedetomidineMigraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .	Cancer, Migraine, SEP	Non applicable	Traitement symptomatique	Portugal	À vérifier
FentanylMigraine attacks were frequently diagnosed in the emergency departments. Also intravenous metoclopramide was a commonly used drug in the acute abortive treatment of migraine. However, the role of metoclopramide was based on three randomized, placebo-controlled studies, which were carried out with relatively few patients. Those trials suggested that metoclopramide produced larger improvements in visual analog scale (VAS) scores, however they revealed conflicting results and had significant methodological problems (risk of bias, allocation of concealment, intention-to-treat analysis). The investigators aimed to analyse the effects of intravenous metoclopramide in acute migraine attacks comparing with placebo.	Cancer, Migraine	Non applicable	À vérifier	Portugal	À vérifier
MidazolamThe goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together. Most drugs are broken down and cleared in the body via cytochrome P450 enzymes in the liver. The metabolism and clearance of certain drugs can be affected by other drugs when dosed together. To evaluate the impact of BMS-984923 on the clearance of other medications, we will investigate three known pathways which may be impacted by BMS-984923. In this study participants will take one dose of the three known medications, midazolam, caffeine and dextromethorphan together. These drugs are known to be cleared by different cytochrome P450 enzymes. Blood will be collected to evaluate the exposure and clearance of these medications and their primary metabolites. Study participants will then be administered BMS-984923 for 18-days. On the 18th Day of BMS-984923 dosing, participants will again be co-administering midazolam, caffeine and dextromethorphan. Blood will be collected again, and the concentration of each drug will be measured. We will learn in this study if BMS-984923 changes the exposure and metabolism of the known drugs. These results will inform how BMS-984923 can be administered to patients who take multiple medications.	Alzheimer, Cancer	Non applicable	À vérifier	Portugal	À vérifier
DexmedetomidineMigraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .	Migraine	Non applicable	Traitement symptomatique	Egypt	À vérifier
DexmedetomidineMigraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .	Cancer	Non applicable	Traitement symptomatique	Portugal	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Dexmedetomidine	Cancer	Non applicable	NCT07926542	DEX-EBUS — Dexmedetomidine as an add-on Sedative for Endobronchial Ultrasound	COMPLETED
Dexmedetomidine	Migraine	Non applicable	NCT07769255	Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine	RECRUITING

Publications

6

Molécule	Indication / population	Titre	Journal	Date
Fentanyl		Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinical Study.	Journal of investigative surgery : the official journal of the Academy of Surgical Research
Fentanyl		Encephalopathy following subcutaneous administration of Brixadi® extended-release buprenorphine.	Toxicology reports
Fentanyl		Sanctioning the supply chain: Analyzing US executive orders on tariffs as a tool against the fentanyl crisis.	Global public health
Midazolam		Efficacy and safety of Dimdazenil in primary insomnia and depressive episodes/bipolar depressive episode with insomnia: A post-marketing, randomized, open-label, positive-controlled study.	Journal of affective disorders
Fentanyl		Validation of a Dried Blood Spot (DBS) Liquid Chromatography - High-Resolution Mass Spectrometry (LC-HRMS) workflow for simultaneous identification of emerging opioids.	Forensic science international
Fentanyl		PF5190457 reduces fentanyl intake and seeking with a low risk pharmacological profile in male rats.	The Journal of pharmacology and experimental therapeutics